Literature DB >> 22789554

Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome.

Arie R Gafson1, Olivia Goodkin, Richard Begent.   

Abstract

Palmar-Plantar syndrome (PPS) is a common side effect of oral capecitabine--a chemotherapeutic agent used as an adjuvant treatment for colorectal cancer. A 66-year-old man suffering from grade II PPS described how Germolene New Skin, a topical healing agent, provided relief from the pain associated with this syndrome and a return to normal function. The patient's observations form the basis for some interesting hypotheses regarding the natural progression of PPS and the potential of New Skin to alleviate pain. Caution must be exercised at this stage as these are single case observations; however, they may be worthy of further exploration in a randomised controlled clinical trial.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22789554      PMCID: PMC3029122          DOI: 10.1136/bcr.04.2010.2869

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.

Authors:  Yoon-Koo Kang; Sung Sook Lee; Dok Hyun Yoon; So Young Lee; Young Ju Chun; Min Sun Kim; Min-Hee Ryu; Heung-Moon Chang; Jae-Lyun Lee; Tae Won Kim
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

2.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Authors:  P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.

Authors:  Samer Abushullaih; Everardo D Saad; Mark Munsell; Paulo M Hoff
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

Review 4.  Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer.

Authors:  Jim Cassidy
Journal:  Clin Colorectal Cancer       Date:  2005-04       Impact factor: 4.481

Review 5.  Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.

Authors:  E Nagore; A Insa; O Sanmartín
Journal:  Am J Clin Dermatol       Date:  2000 Jul-Aug       Impact factor: 7.403

Review 6.  Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.

Authors:  Werner Scheithauer; Joanne Blum
Journal:  Oncology (Williston Park)       Date:  2004-08       Impact factor: 2.990

Review 7.  Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).

Authors:  Yvonne Lassere; Paulo Hoff
Journal:  Eur J Oncol Nurs       Date:  2004       Impact factor: 2.398

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.